CIMAB S.A. and Neuronic Mexicana S.A. de C.V.are announcing today the creation of IncuBIO S.A.

CIMAB S.A. and Neuronic Mexicana S.A. de C.V.are announcing today the creation of IncuBIO S.A., a Joint Venture Company incorporated in the Mariel Special Development Zone.

IncuBIO has been designed with the special purpose to attract risk capital. Future investors will have the opportunity to acquire IncuBIO’s shares and contribute to increase product(s) value by funding clinical trials in major markets.

For accomplishing this, IncuBIO holds an exclusive license for the development and commercialization of innovative biotech products, including NeuroEPO, one of the most promising assets in the pipeline of the Center of Molecular Immunology (CIM), a leading Cuban biotech enterprise.

NeuroEPO is an intranasal formulation of recombinant human Erythropoietin with low sialic acid content, which is being clinically evaluated in Cuba for the treatment of several neurodegenerative diseases, like Alzheimer’s, Parkinson’s and Ataxia.

After a recently finished proof of concept trial, NeuroEPO showed evidence of acting as a brain homeostatic regulator, reducing cognitive impairment in Alzheimer patients.

CIMAB S.A. is a Cuban company, devoted to business development and administration through its direct participation inall major markets alliances involving the main biotech assets owned byits parent company, the CIM. With the incorporation of IncuBIO is now shareholder of five Joint Venture Companies located in China, Thailand, Singapore and Cuba.

Neuronic Mexicana S.A. de C.V. is a Mexican company, established since 1996, engaged in the commercialization of biopharmaceutical products and medical equipment.